11 Best Short Squeeze Stocks to Buy Now

Page 4 of 10

7. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Short Float: 28.69%

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) holds a rank in our list of 11 best short squeeze stocks to buy now. The company’s stocks surge following the approval of the U.S. FDA Priority Review for sNDA for Revuforj (revumenib).

Headquartered in Massachusetts, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage oncology company engaged in developing novel combination therapies for cancer. The lead products include Revumenib, a menin inhibitor for acute leukemia, and Niktimvo (axatilimab-csfr) for chronic graft-versus-host disease. Currently, the company’s clinical pipeline also looks into applications in solid tumors and inflammatory conditions.

On June 24, 2025, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced receiving a U.S. FDA Priority Review for its supplemental New Drug Application (sNDA) for Revuforj (revumenib) for the treatment of relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML). This sNDA, reviewed under the FDA’s Real-Time Oncology Review (RTOR) program, allows for a more efficient review and close engagement between the sponsor and FDA. The Prescription Drug User Fee Act (PDUFA) target action date is October 25, 2025.

Following the announcements, many analysts have reiterated their Buy rating on the stock. The 1-year median price target for the stock, as per CNN’s 12 analysts, is $35, a 169.85% uptick from its current closing price as of August 12, 2025. Also, the company’s stocks are vulnerable to sudden price surges on positive news, with an elevated short float of 28.69% that tends to heighten the risk for short sellers.

Page 4 of 10